Skip to content
Disclosery

Commodore Capital LP

Follow

13F filer, CIK 1831942, NEW YORK, NY

Commodore Capital LP reported $2,048,436,266 across 37 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14. Its ten largest share positions make up 58.91% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001831942-25-000023

Period
2025-09-30
Reported value
$2.05B
Holdings
37
Top 10 weight
58.91%
New
7
Sold out
3

Part of the filer group Commodore Capital LP

  • Commodore Capital Master LP
  • Michael Kramarz
  • Robert Egen Atkinson
How groups are built

Stakes and trades reported after 2025-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SGMT SAGIMET BIOSCIENCES INC: 13G 5,507,752 shares, 7.6% of the class, 13G filed 2026-10-07, 0001831942-26-000045Timeline
    Accepted , ingested
  • SRZN SURROZEN INC: 13G 885,000 shares, 7.5% of the class, 13G filed 2026-10-01, 0001831942-26-000044Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
COGTadded+4,938,836$70.9M
AMLXnew+4,075,478$55.4M
SLNOadded+740,000$50M
TERNnew+5,700,000$42.8M
ASMBnew+1,000,000$25.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CDTXreduced-590,000-$56.5M
SRRKexited-1,450,000-$51.4M
VRDNreduced-1,675,000-$36.1M
MIND MEDICINE MINDMED INCreduced-1,775,000-$20.9M
VERAexited-800,000-$18.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001831942-25-000023, largest first. % of portfolio is the value over $2,048,436,266, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,350,000 shares; 2024Q4: 3,874,182 shares; 2025Q1: 4,472,840 shares; 2025Q2: 3,525,000 shares; 2025Q3: 3,525,000 shares 3,525,000$332M16.2%0
NUVLNUVALENT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 940,000 shares; 2024Q4: 1,621,600 shares; 2025Q1: 1,855,000 shares; 2025Q2: 1,375,000 shares; 2025Q3: 1,400,000 shares 1,400,000$121M5.91%+25,000Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,700,000 shares; 2024Q4: 2,740,000 shares; 2025Q1: 2,325,000 shares; 2025Q2: 3,025,000 shares; 2025Q3: 2,700,000 shares 2,700,000$108M5.29%-325,000Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 7,539,930 shares; 2024Q4: 6,881,629 shares; 2025Q1: 8,892,816 shares; 2025Q2: 2,311,164 shares; 2025Q3: 7,250,000 shares 7,250,000$104M5.08%+4,938,836Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,100,000 shares; 2024Q4: 4,205,000 shares; 2025Q1: 4,675,000 shares; 2025Q2: 4,692,809 shares; 2025Q3: 4,692,809 shares 4,692,809$96.1M4.69%0Timeline
AGIOAGIOS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 2,185,000 shares; 2025Q2: 2,325,000 shares; 2025Q3: 2,338,287 shares 2,338,287$93.9M4.58%+13,287Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,900,000 shares; 2024Q4: 2,300,000 shares; 2025Q1: 1,950,000 shares; 2025Q2: 2,450,000 shares; 2025Q3: 3,096,754 shares 3,096,754$92.9M4.54%+646,754Timeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,260,000 shares; 2024Q4: 1,525,000 shares; 2025Q1: 1,150,000 shares; 2025Q2: 610,000 shares; 2025Q3: 1,350,000 shares 1,350,000$91.3M4.46%+740,000Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 13,350,000 shares; 2025Q3: 17,000,000 shares 17,000,000$88.7M4.33%+3,650,000Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,618,937 shares; 2024Q4: not reported; 2025Q1: 3,200,000 shares; 2025Q2: 3,450,000 shares; 2025Q3: 3,028,335 shares 3,028,335$78.3M3.82%-421,665Timeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,350,000 shares; 2024Q4: 2,218,425 shares; 2025Q1: 2,367,578 shares; 2025Q2: 3,298,289 shares; 2025Q3: 2,850,000 shares 2,850,000$69.1M3.37%-448,289Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,550,124 shares; 2024Q4: 2,400,000 shares; 2025Q1: 3,600,000 shares; 2025Q2: 4,875,000 shares; 2025Q3: 3,200,000 shares 3,200,000$69.1M3.37%-1,675,000Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,075,000 shares; 2025Q3: 1,025,000 shares 1,025,000$68.1M3.32%-50,000Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,911,433 shares; 2024Q4: 1,911,433 shares; 2025Q1: 1,911,433 shares; 2025Q2: 1,911,433 shares; 2025Q3: 2,418,476 shares 2,418,476$60.3M2.95%+507,043Timeline
CDTXCIDARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,175,000 shares; 2025Q3: 585,000 shares 585,000$56M2.73%-590,000Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 4,075,478 shares 4,075,478$55.4M2.7%newTimeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 950,000 shares; 2025Q2: 3,100,000 shares; 2025Q3: 3,375,000 shares 3,375,000$47.2M2.3%+275,000Timeline
TERNTERNS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 5,700,000 shares 5,700,000$42.8M2.09%newTimeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 750,000 shares; 2025Q3: 750,000 shares 750,000$42.5M2.07%0Timeline
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,000,000 shares; 2024Q4: 4,308,425 shares; 2025Q1: 4,525,000 shares; 2025Q2: 5,000,000 shares; 2025Q3: 3,225,000 shares 3,225,000$38M1.86%-1,775,000
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,650,000 shares; 2024Q4: 3,000,000 shares; 2025Q1: 3,978,907 shares; 2025Q2: 3,948,653 shares; 2025Q3: 3,780,055 shares 3,780,055$34.9M1.71%-168,598Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,369,714 shares; 2024Q4: 1,419,714 shares; 2025Q1: 1,419,714 shares; 2025Q2: 1,419,714 shares; 2025Q3: 1,753,054 shares 1,753,054$33.7M1.65%+333,340Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,988,084 shares; 2024Q4: 1,988,084 shares; 2025Q1: 1,988,084 shares; 2025Q2: 1,988,084 shares; 2025Q3: 1,988,084 shares 1,988,084$33.3M1.63%0Timeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 500,000 shares; 2025Q1: 500,000 shares; 2025Q2: 500,000 shares; 2025Q3: 500,000 shares 500,000$30.3M1.48%0Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,000,000 shares 1,000,000$25.6M1.25%newTimeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 7,692,300 shares; 2025Q3: 7,692,300 shares 7,692,300$24.5M1.2%0Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,500,000 shares 1,500,000$23.7M1.16%newTimeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,500,000 shares; 2025Q3: 1,500,000 shares 1,500,000$12.6M0.62%0Timeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 290,000 shares; 2024Q4: 290,000 shares; 2025Q1: 290,000 shares; 2025Q2: 290,000 shares; 2025Q3: 290,000 shares 290,000$11.5M0.56%0Timeline
PEPGPEPGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,357,319 shares 2,357,319$10.9M0.53%newTimeline
ENTAENANTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 800,000 shares 800,000$9.58M0.47%newTimeline
SABSSAB BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 4,401,500 shares 4,401,500$8.85M0.43%newTimeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 5,925,000 shares; 2025Q1: 5,344,432 shares; 2025Q2: 5,397,488 shares; 2025Q3: 5,397,488 shares 5,397,488$8.74M0.43%0Timeline
FRNMPERCEPTIVE CAP SOLUTIONS CORQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 750,000 shares; 2024Q4: 750,000 shares; 2025Q1: 750,000 shares; 2025Q2: 750,000 shares; 2025Q3: 750,000 shares 750,000$7.92M0.39%0Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 483,000 shares; 2024Q4: 483,000 shares; 2025Q1: 483,000 shares; 2025Q2: 483,000 shares; 2025Q3: 483,000 shares 483,000$6.14M0.3%0Timeline
VTGNVISTAGEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,575,000 shares; 2024Q4: 1,575,000 shares; 2025Q1: 1,575,000 shares; 2025Q2: 1,575,000 shares; 2025Q3: 1,575,000 shares 1,575,000$5.59M0.27%0Timeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 453,686 shares; 2025Q3: 450,829 shares 450,829$5.36M0.26%-2,857Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SRRKSCHOLAR ROCK HLDG CORP1,450,000$51.4Mshares
VERAVERA THERAPEUTICS INC800,000$18.8Mshares
NGNENEUROGENE INC427,866$6.4Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001831942-25-000023 base2025-11-14acceptance time not in the bulk data set